Clinical Trial

The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Trial

Name: The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Trial — clinical trial record (NCT07391319)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The main objective of the study is to evaluate the efficacy and safety of Neovasculgen® in a course dose of 2.4 mg in combination with standard drug therapy in patients with unilateral neuroischemic form of diabetic foot syndrome.

Trial Details

NCT Number	NCT07391319
Lead Sponsor	JSC NextGen
Conditions	Ulcer Foot, Mellitus Diabetes
Enrollment	144 participants
Start Date	2025-02-11
Primary Completion	2027-03-31 (estimated)
Study Completion	2027-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-05